Search





Search





Markets
/
Stocks
/
nasdaq-ipsc
/

Century Therapeutics Inc

IPSC

Add to Watchlist

2.340USD

-0.040-1.68%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

422.03MMarket Cap

LossP/E TTM



Century Therapeutics Inc

2.340

-0.040-1.68%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Century Therapeutics Inc

Currency: USD Updated: 2026-05-15

Key Insights

Century Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 61 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.40.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Century Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

61 / 382

Overall Ranking

173 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Century Therapeutics Inc Highlights

StrengthsRisks

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 4784.30% year-on-year.

Undervalued

The company’s latest PE is -2.10, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 114.13M shares, increasing 37.39% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 1.35M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.11.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

4.400

Target Price

+84.87%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Century Therapeutics Inc is 8.16, ranking 44 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 128.27%.

Score

Industry at a Glance

Previous score

8.16

Change



Financials

6.70

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.39

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.72

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Century Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Century Therapeutics Inc is 8.66, ranking 29 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.10, which is -84.85% below the recent high of -0.32 and -1016.87% above the recent low of -23.49.

Score

Industry at a Glance

Previous score

8.66

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 61/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Century Therapeutics Inc is 7.60, ranking 281 out of 382 in the Biotechnology & Medical Research industry. The average price target is 2.00, with a high of 8.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

4.400

Target Price

+84.87%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Century Therapeutics Inc

IPSC

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

argenx SE

ARGX

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Century Therapeutics Inc is 7.09, ranking 102 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.57 and the support level at 2.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.18

Change

-0.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.008

Buy

RSI(14)

52.575

Neutral

STOCH(KDJ)(9,3,3)

72.493

Neutral

ATR(14)

0.119

High Vlolatility

CCI(14)

60.418

Neutral

Williams %R

24.000

Buy

TRIX(12,20)

-0.001

Sell

StochRSI(14)

55.534

Neutral

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.316

Buy

MA10

2.310

Buy

MA20

2.296

Buy

MA50

2.332

Buy

MA100

2.090

Buy

MA200

1.316

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Century Therapeutics Inc is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 63.28%, representing a quarter-over-quarter increase of 64.36%. The largest institutional shareholder is Steven Cohen, holding a total of 5.96M shares, representing 3.31% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

TCG Crossover Management, LLC

17.75M

RA Capital Management, LP

17.75M

Deep Track Capital LP

13.49M

Bayer AG

12.68M

Versant Ventures

12.17M

Commodore Capital LP

8.70M

VR Adviser, LLC

8.70M

Fujifilm Holdings Corp

6.96M

Point72 Asset Management, L.P.

Star Investors

5.96M

-0.00%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Century Therapeutics Inc is 2.04, ranking 246 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.56. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.